New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Positive opinions based on significant survival benefit
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
Subscribe To Our Newsletter & Stay Updated
